查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
症候群多重診斷的全球市場 - 產業趨勢、至2029年的預測
市場調查報告書
商品編碼
1110917

症候群多重診斷的全球市場 - 產業趨勢、至2029年的預測

Global Syndromic Multiplex Diagnostic Market - Industry Trends and Forecast to 2029
出版日期: | 出版商: Data Bridge Market Research | 英文 297 Pages | 商品交期: 請詢問到貨日

價格

全球症候群多重診斷的市場規模，在2022年～2029年的預測期間中預計以8.7％的年複合成長率成長。市場成長的促進因素，是感染疾病擴大增加，技術進步，早期診斷意識高漲等。

本報告提供全球症候群多重診斷市場相關調查分析，市場產業趨勢和預測，市場區隔分析，企業簡介等資訊。

目錄

第1章 簡介

第2章 市場區隔

第3章 摘要整理

第4章 重要考察

  • PESTEL分析
  • 波特的五力分析
  • 前3名企業的各面板的市場佔有率(2021年)

第5章 全球症候群多重診斷市場:法規

第6章 市場概要

  • 促進因素
  • 阻礙因素
  • 機會
  • 課題

第7章 全球症候群多重診斷市場:各產品、服務

  • 概要
  • 試劑、消耗品
  • 器具，軟體、配件
  • 服務

第8章 全球症候群多重診斷市場:各感染類型

  • 概要
  • 病毒
  • 細菌
  • 寄生蟲
  • 真菌

第9章 全球症候性多重診斷市場:各疾病

  • 概要
  • 呼吸系統感染疾病
  • 腸胃炎
  • 性感染疾病
  • 敗血症
  • 腦膜炎
  • 其他

第10章 全球症候群多重診斷市場:各面板類型

  • 概要
  • 呼吸系統面板
  • 腸胃面板
  • 性感染疾病面板
  • 敗血症面板
  • 腦膜炎面板
  • 其他

第11章全球症候群多重診斷市場:各終端用戶

  • 概要
  • 醫院
  • 臨床檢驗室
  • 製藥、生物科技企業
  • 研究機關
  • 其他

第12章 全球症候群多重診斷市場:各地區

  • 概要
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞士
    • 俄羅斯
    • 比利時
    • 土耳其
    • 其他的歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 新加坡
    • 泰國
    • 馬來西亞
    • 印尼
    • 菲律賓
    • 其他的亞太地區
  • 南美
    • 巴西
    • 阿根廷
    • 其他的南美
  • 中東、非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 埃及
    • 其他的中東、非洲

第13章 全球症候群多重診斷市場:企業形勢

  • 企業佔有率分析:世界
  • 企業佔有率分析:北美
  • 企業佔有率分析:歐洲
  • 企業佔有率分析:亞太地區

第14章 SWOT分析

第15章 企業簡介

  • BIOFIRE DIAGNOSTICS(A SUBSIDIARY OF BIOMERIEUX SA)
  • F. HOFFMANN-LA ROCHE LTD
  • LUMINEX CORPORATION. A DIASORIN COMPANY
  • CEPHEID(A SUBSIDIARY OF DANAHER)
  • QIAGEN
  • ABBOTT
  • AKONNI BIOSYSTEMS, INC.
  • APPLIED BIOCODE, INC.
  • BD
  • BIOCARTIS
  • BIO-RAD LABORATORIES, INC.
  • BOSCH HEALTHCARE SOLUTIONS GMBH(A SUBSIDIARY OF ROBERT BOSCH GMBH)
  • CURETIS(A SUBSIDIARY OF OPGEN, INC.)
  • HOLOGIC, INC.
  • MIRXES PTE LTD.
  • NANOMIX, INC.
  • PROMINEX INC.
  • QUANTUMDX GROUP LTD.
  • SEEGENE INC.
  • SIEMENS HEALTHCARE GMBH
  • THERMOFISHER SCIENTIFIC INC.

第16章 問卷調查

第17章 相關報告

The global syndromic multiplex diagnostic market is projected to register a CAGR of 8.7% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2020, and the forecast period is 2022 to 2029.

Market Segmentation:

Global Syndromic Multiplex Diagnostic Market - By Product and Services (Reagents & Consumables, Instruments, Software & Accessories and Services), Infection type (Viral, Bacterial, Parasites and Fungal), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Sepsis, Meningitis and Others), Panels Type (Respiratory Panel, GI-Enteric Panel, SexuallyTransmitted Disease Panel, Blood-Sepsis Panel, Meningitis panel and Others), End User (Clinical Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies, Research Institutes and Others), Country (U.S., Canada, Mexico, Germany, France ,U.K, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippine, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) - Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of global syndromic multiplex diagnostic market are:

Increase in prevalence of infectious diseases

Growing technological advancement

Increasing awareness towards early diagnosis

Strategic initiatives

Market Players:

The major companies which are dealing in the global syndromic multiplex diagnostic are listed below:

BioFire Diagnostics (A Subsidiary of bioMerieux SA)

Seegene Inc.

Luminex Corporation. A DiaSorin Company

F. Hoffmann-La Roche Ltd

BD

Bio-Rad Laboratories, Inc.

Cepheid (A Subsidiary of Danaher)

QIAGEN

Abbott

Hologic, Inc.

Thermo Fisher Scientific Inc.

Siemens Healthcare GmbH

Akonni Biosystems, Inc.

Biocartis

QuantuMDx Group Ltd.

Bosch Healthcare Solutions GmbH (A Subsidiary Of Robert Bosch GmbH)

Applied BioCode, Inc.

Prominex Inc.

Nanomix, Inc

Curetis (A Subsidiary of OpGen, Inc.)

MiRXES Pte Ltd.

TABLE OF CONTENTS

1 INTRODUCTION 28

  • 1.1 OBJECTIVES OF THE STUDY 28
  • 1.2 MARKET DEFINITION 28
  • 1.3 OVERVIEW OF GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET 28
  • 1.4 LIMITATIONS 30
  • 1.5 MARKETS COVERED 30

2 MARKET SEGMENTATION 33

  • 2.1 MARKETS COVERED 33
  • 2.2 GEOGRAPHICAL SCOPE 34
  • 2.3 YEARS CONSIDERED FOR THE STUDY 35
  • 2.4 CURRENCY AND PRICING 35
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 36
  • 2.6 MULTIVARIATE MODELLING 39
  • 2.7 PRODUCT AND SERVICES LIFELINE CURVE 39
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 40
  • 2.9 DBMR MARKET POSITION GRID 41
  • 2.10 MARKET END USER COVERAGE GRID 42
  • 2.11 VENDOR SHARE ANALYSIS 43
  • 2.12 SECONDARY SOURCES 44
  • 2.13 ASSUMPTIONS 44

3 EXECUTIVE SUMMARY 45

4 PREMIUM INSIGHTS 47

  • 4.1 PESTEL ANALYSIS 50
  • 4.2 PORTER'S FIVE FORCES 51
  • 4.3 MARKET SHARE PER PANEL, FOR TOP 3 PLAYERS (2021) 52

5 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: REGULATIONS 53

6 MARKET OVERVIEW 56

  • 6.1 DRIVERS 58
    • 6.1.1 RISING PREVALENCE OF INFECTIOUS DISEASES 58
    • 6.1.2 RISING ADOPTION OF MOLECULAR DIAGNOSTICS TECHNIQUES 59
    • 6.1.3 INCREASING REGULATORY APPROVAL FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) TESTING 60
    • 6.1.4 INCREASING DEMAND FOR FAST AND ACCURATE DIAGNOSTIC RESULTS 60
  • 6.2 RESTRAINTS 61
    • 6.2.1 HIGH COST OF DIAGNOSTIC PRODUCTS 61
    • 6.2.2 EXPLICIT LIMITATION OF SYNDROMIC MULTIPLEX DIAGNOSTIC 61
  • 6.3 OPPORTUNITIES 62
    • 6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS 62
    • 6.3.2 RISING DIAGNOSTIC HEALTHCARE EXPENDITURE 62
    • 6.3.3 INTRODUCTION OF TECHNOLOGICAL ADVANCED PRODUCTS 64
  • 6.4 CHALLENGES 65
    • 6.4.1 PRODUCT RECALLS 65
    • 6.4.2 LACK OF SKILLED PROFESSIONALS AND BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS 65

7 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES 66

  • 7.1 OVERVIEW 67
  • 7.2 REAGENTS & CONSUMABLES 70
  • 7.3 INSTRUMENTS, SOFTWARE & ACCESSORIES 70
  • 7.4 SERVICES 71

8 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE 73

  • 8.1 OVERVIEW 74
  • 8.2 VIRAL 77
    • 8.2.1 CORONAVIRUS 78
    • 8.2.2 INFLUENZA VIRUS 78
    • 8.2.3 ADENOVIRUS 78
    • 8.2.4 RHINOVIRUS 78
    • 8.2.5 ROTAVIRUS 78
    • 8.2.6 OTHERS 78
  • 8.3 BACTERIAL 79
    • 8.3.1 PNEUMONIAE 80
    • 8.3.2 BORDETELLA PERTUSSIS 80
    • 8.3.3 STAPHYLOCOCCUS 80
    • 8.3.4 OTHERS 80
  • 8.4 PARASITES 80
  • 8.5 FUNGAL 81

9 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE 83

  • 9.1 OVERVIEW 84
  • 9.2 RESPIRATORY INFECTIONS 87
  • 9.3 GASTROENTERITIS 88
  • 9.4 SEXUALLY TRANSMITTED INFECTIONS 88
  • 9.5 SEPSIS 89
  • 9.6 MENINGITIS 90
  • 9.7 OTHERS 91

10 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE 93

  • 10.1 OVERVIEW 94
  • 10.2 RESPIRATORY PANEL 97
  • 10.3 GI-ENTERIC PANEL 97
  • 10.4 SEXUALLY TRANSMITTED DISEASE PANEL 98
  • 10.5 BLOOD-SEPSIS PANEL 99
  • 10.6 MENINGITIS PANEL 100
  • 10.7 OTHERS 101

11 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER 102

  • 11.1 OVERVIEW 103
  • 11.2 HOSPITALS 106
  • 11.3 CLINICAL LABORATORIES 106
  • 11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 107
  • 11.5 RESEARCH INSTITUTES 108
  • 11.6 OTHERS 109

12 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION 110

  • 12.1 OVERVIEW 111
  • 12.2 NORTH AMERICA 116
    • 12.2.1 U.S. 123
    • 12.2.2 CANADA 126
    • 12.2.3 MEXICO 129
  • 12.3 EUROPE 132
    • 12.3.1 GERMANY 139
    • 12.3.2 U.K. 142
    • 12.3.3 FRANCE 145
    • 12.3.4 ITALY 148
    • 12.3.5 SPAIN 151
    • 12.3.6 NETHERLANDS 154
    • 12.3.7 SWITZERLAND 157
    • 12.3.8 RUSSIA 160
    • 12.3.9 BELGIUM 163
    • 12.3.10 TURKEY 166
    • 12.3.11 REST OF EUROPE 169
  • 12.4 ASIA-PACIFIC 170
    • 12.4.1 CHINA 177
    • 12.4.2 JAPAN 180
    • 12.4.3 INDIA 183
    • 12.4.4 SOUTH KOREA 186
    • 12.4.5 AUSTRALIA 189
    • 12.4.6 SINGAPORE 192
    • 12.4.7 THAILAND 195
    • 12.4.8 MALAYSIA 198
    • 12.4.9 INDONESIA 201
    • 12.4.10 PHILIPPINES 204
    • 12.4.11 REST OF ASIA-PACIFIC 207
  • 12.5 SOUTH AMERICA 208
    • 12.5.1 BRAZIL 215
    • 12.5.2 ARGENTINA 218
    • 12.5.3 REST OF SOUTH AMERICA 221
  • 12.6 MIDDLE EAST AND AFRICA 222
    • 12.6.1 SOUTH AFRICA 229
    • 12.6.2 SAUDI ARABIA 232
    • 12.6.3 U.A.E 235
    • 12.6.4 ISRAEL 238
    • 12.6.5 EGYPT 241
    • 12.6.6 REST OF MIDDLE EAST AND AFRICA 244

13 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY LANDSCAPE 245

  • 13.1 COMPANY SHARE ANALYSIS: GLOBAL 245
  • 13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 246
  • 13.3 COMPANY SHARE ANALYSIS: EUROPE 247
  • 13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 248

14 SWOT ANALYSIS 249

15 COMPANY PROFILE 250

  • 15.1 BIOFIRE DIAGNOSTICS (A SUBSIDIARY OF BIOMERIEUX SA) 250
    • 15.1.1 COMPANY SNAPSHOT 250
    • 15.1.2 REVENUE ANALYSIS 250
    • 15.1.3 COMPANY SHARE ANALYSIS 251
    • 15.1.4 PRODUCT PORTFOLIO 251
    • 15.1.5 RECENT DEVELOPMENTS 252
  • 15.2 F. HOFFMANN-LA ROCHE LTD 253
    • 15.2.1 COMPANY SNAPSHOT 253
    • 15.2.2 REVENUE ANALYSIS 253
    • 15.2.3 COMPANY SHARE ANALYSIS 254
    • 15.2.4 PRODUCT PORTFOLIO 254
    • 15.2.5 RECENT DEVELOPMENT 255
  • 15.3 LUMINEX CORPORATION. A DIASORIN COMPANY 256
    • 15.3.1 COMPANY SNAPSHOT 256
    • 15.3.2 RECENT FINANCIALS 256
    • 15.3.3 COMPANY SHARE ANALYSIS 257
    • 15.3.4 PRODUCT PORTFOLIO 257
    • 15.3.5 RECENT DEVELOPMENT 258
  • 15.4 CEPHEID (A SUBSIDIARY OF DANAHER) 259
    • 15.4.1 COMPANY SNAPSHOT 259
    • 15.4.2 RECENT FINANCIALS 259
    • 15.4.3 COMPANY SHARE ANALYSIS 260
    • 15.4.4 PRODUCT PORTFOLIO 260
    • 15.4.5 RECENT DEVELOPMENTS 261
  • 15.5 QIAGEN 262
    • 15.5.1 COMPANY SNAPSHOT 262
    • 15.5.2 RECENT FINANCIALS 262
    • 15.5.3 COMPANY SHARE ANALYSIS 263
    • 15.5.4 PRODUCT PORTFOLIO 263
    • 15.5.5 RECENT DEVELOPMENT 263
  • 15.6 ABBOTT 264
    • 15.6.1 COMPANY SNAPSHOT 264
    • 15.6.2 REVENUE ANALYSIS 264
    • 15.6.3 PRODUCT PORTFOLIO 265
    • 15.6.4 RECENT DEVELOPMENT 265
  • 15.7 AKONNI BIOSYSTEMS, INC. 266
    • 15.7.1 COMPANY SNAPSHOT 266
    • 15.7.2 PRODUCT PORTFOLIO 266
    • 15.7.3 RECENT DEVELOPMENT 266
  • 15.8 APPLIED BIOCODE, INC. 267
    • 15.8.1 COMPANY SNAPSHOT 267
    • 15.8.2 PRODUCT PORTFOLIO 267
    • 15.8.3 RECENT DEVELOPMENTS 268
  • 15.9 BD 269
    • 15.9.1 COMPANY SNAPSHOT 269
    • 15.9.2 REVENUE ANALYSIS 269
    • 15.9.3 PRODUCT PORTFOLIO 270
    • 15.9.4 RECENT DEVELOPMENTS 270
  • 15.10 BIOCARTIS 271
    • 15.10.1 COMPANY SNAPSHOT 271
    • 15.10.2 REVENUE ANALYSIS 271
    • 15.10.3 PRODUCT PORTFOLIO 272
    • 15.10.4 RECENT DEVELOPMENT 272
  • 15.11 BIO-RAD LABORATORIES, INC. 273
    • 15.11.1 COMPANY SNAPSHOT 273
    • 15.11.2 REVENUE ANALYSIS 273
    • 15.11.3 PRODUCT PORTFOLIO 274
    • 15.11.4 RECENT DEVELOPMENT 274
  • 15.12 BOSCH HEALTHCARE SOLUTIONS GMBH (A SUBSIDIARY OF ROBERT BOSCH GMBH) 275
    • 15.12.1 COMPANY SNAPSHOT 275
    • 15.12.2 REVENUE ANALYSIS 275
    • 15.12.3 PRODUCT PORTFOLIO 276
    • 15.12.4 RECENT DEVELOPMENT 276
  • 15.13 CURETIS (A SUBSIDIARY OF OPGEN, INC.) 277
    • 15.13.1 COMPANY SNAPSHOT 277
    • 15.13.2 RECENT FINANCIALS 277
    • 15.13.3 PRODUCT PORTFOLIO 278
    • 15.13.4 RECENT DEVELOPMENTS 278
  • 15.14 HOLOGIC, INC. 279
    • 15.14.1 COMPANY SNAPSHOT 279
    • 15.14.2 RECENT FINANCIALS 279
    • 15.14.3 PRODUCT PORTFOLIO 280
    • 15.14.4 RECENT DEVELOPMENT 280
  • 15.15 MIRXES PTE LTD. 281
    • 15.15.1 COMPANY SNAPSHOT 281
    • 15.15.2 PRODUCT PORTFOLIO 281
    • 15.15.3 RECENT DEVELOPMENT 281
  • 15.16 NANOMIX, INC. 282
    • 15.16.1 COMPANY SNAPSHOT 282
    • 15.16.2 PRODUCT PORTFOLIO 282
    • 15.16.3 RECENT DEVELOPMENT 282
  • 15.17 PROMINEX INC. 283
    • 15.17.1 COMPANY SNAPSHOT 283
    • 15.17.2 PRODUCT PORTFOLIO 283
    • 15.17.3 RECENT DEVELOPMENT 283
  • 15.18 QUANTUMDX GROUP LTD. 284
    • 15.18.1 COMPANY SNAPSHOT 284
    • 15.18.2 PRODUCT PORTFOLIO 284
    • 15.18.3 RECENT DEVELOPMENTS 284
  • 15.19 SEEGENE INC. 285
    • 15.19.1 COMPANY SNAPSHOT 285
    • 15.19.2 REVENUE ANALYSIS 285
    • 15.19.3 PRODUCT PORTFOLIO 286
    • 15.19.4 RECENT DEVELOPMENTS 289
  • 15.20 SIEMENS HEALTHCARE GMBH 290
    • 15.20.1 COMPANY SNAPSHOT 290
    • 15.20.2 RECENT FINANCIALS 290
    • 15.20.3 PRODUCT PORTFOLIO 291
    • 15.20.4 RECENT DEVELOPMENT 291
  • 15.21 THERMOFISHER SCIENTIFIC INC. 292
    • 15.21.1 COMPANY SNAPSHOT 292
    • 15.21.2 RECENT FINANCIALS 292
    • 15.21.3 PRODUCT PORTFOLIO 293
    • 15.21.4 RECENT DEVELOPMENT 293

16 QUESTIONNAIRE 294

17 RELATED REPORTS 297

LIST OF TABLES

  • TABLE 1 COST OF THE PRODUCT 61
  • TABLE 2 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION) 69
  • TABLE 3 GLOBAL REAGENTS & CONSUMABLES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 70
  • TABLE 4 GLOBAL INSTRUMENTS, SOFTWARE & ACCESSORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 71
  • TABLE 5 GLOBAL SERVICES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 72
  • TABLE 6 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 76
  • TABLE 7 GLOBAL VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 77
  • TABLE 8 GLOBAL VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 78
  • TABLE 9 GLOBAL BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 79
  • TABLE 10 GLOBAL BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 80
  • TABLE 11 GLOBAL PARASITES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 81
  • TABLE 12 GLOBAL FUNGAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 82
  • TABLE 13 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 86
  • TABLE 14 GLOBAL RESPIRATORY INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 87
  • TABLE 15 GLOBAL GASTROENTERITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 88
  • TABLE 16 GLOBAL SEXUALLY TRANSMITTED INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 89
  • TABLE 17 GLOBAL SEPSIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 90
  • TABLE 18 GLOBAL MENINGITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 91
  • TABLE 19 GLOBAL OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 92
  • TABLE 20 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 96
  • TABLE 21 GLOBAL RESPIRATORY PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 97
  • TABLE 22 GLOBAL GI-ENTERIC PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 98
  • TABLE 23 GLOBAL SEXUALLY TRANSMITTED DISEASE PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 99
  • TABLE 24 GLOBAL BLOOD-SEPSIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 100
  • TABLE 25 GLOBAL MENINGITIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 101
  • TABLE 26 GLOBAL OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 101
  • TABLE 27 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 105
  • TABLE 28 GLOBAL HOSPITALS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 106
  • TABLE 29 GLOBAL CLINICAL LABORATORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 107
  • TABLE 30 GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 108
  • TABLE 31 GLOBAL RESEARCH INSTITUTES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 108
  • TABLE 32 GLOBAL OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 109
  • TABLE 33 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 115
  • TABLE 34 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 120
  • TABLE 35 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 120
  • TABLE 36 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 120
  • TABLE 37 NORTH AMERICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 121
  • TABLE 38 NORTH AMERICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 121
  • TABLE 39 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 121
  • TABLE 40 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 122
  • TABLE 41 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 122
  • TABLE 42 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 123
  • TABLE 43 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 123
  • TABLE 44 U.S. VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 123
  • TABLE 45 U.S. BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 124
  • TABLE 46 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 124
  • TABLE 47 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 124
  • TABLE 48 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 125
  • TABLE 49 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 126
  • TABLE 50 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 126
  • TABLE 51 CANADA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 126
  • TABLE 52 CANADA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 127
  • TABLE 53 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 127
  • TABLE 54 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 127
  • TABLE 55 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 128
  • TABLE 56 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 129
  • TABLE 57 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 129
  • TABLE 58 MEXICO VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 129
  • TABLE 59 MEXICO BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 130
  • TABLE 60 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 130
  • TABLE 61 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 130
  • TABLE 62 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 131
  • TABLE 63 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 136
  • TABLE 64 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 136
  • TABLE 65 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 136
  • TABLE 66 EUROPE VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 137
  • TABLE 67 EUROPE BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 137
  • TABLE 68 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 137
  • TABLE 69 UROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 138
  • TABLE 70 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 138
  • TABLE 71 GERMANY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 139
  • TABLE 72 GERMANY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 139
  • TABLE 73 GERMANY VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 139
  • TABLE 74 GERMANY BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 140
  • TABLE 75 GERMANY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 140
  • TABLE 76 GERMANY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 140
  • TABLE 77 GERMANY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 141
  • TABLE 78 U.K. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 142
  • TABLE 79 U.K. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 142
  • TABLE 80 U.K. VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 142
  • TABLE 81 U.K. BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 143
  • TABLE 82 U.K. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 143
  • TABLE 83 U.K. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 143
  • TABLE 84 U.K. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 144
  • TABLE 85 FRANCE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 145
  • TABLE 86 FRANCE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 145
  • TABLE 87 FRANCE VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 145
  • TABLE 88 FRANCE BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 146
  • TABLE 89 FRANCE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 146
  • TABLE 90 FRANCE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 146
  • TABLE 91 FRANCE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 147
  • TABLE 92 ITALY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 148
  • TABLE 93 ITALY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 148
  • TABLE 94 ITALY VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 148
  • TABLE 95 ITALY BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 149
  • TABLE 96 ITALY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 149
  • TABLE 97 ITALY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 149
  • TABLE 98 ITALY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 150
  • TABLE 99 SPAIN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 151
  • TABLE 100 SPAIN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 151
  • TABLE 101 SPAIN VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 151
  • TABLE 102 SPAIN BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 152
  • TABLE 103 SPAIN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 152
  • TABLE 104 SPAIN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 152
  • TABLE 105 SPAIN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 153
  • TABLE 106 NETHERLANDS SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 154
  • TABLE 107 NETHERLANDS SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 154
  • TABLE 108 NETHERLANDS VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 154
  • TABLE 109 NETHERLANDS BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 155
  • TABLE 110 NETHERLANDS SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 155
  • TABLE 111 NETHERLANDS SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 155
  • TABLE 112 NETHERLANDS SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 156
  • TABLE 113 SWITZERLAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 157
  • TABLE 114 SWITZERLAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 157
  • TABLE 115 SWITZERLAND VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 157
  • TABLE 116 SWITZERLAND BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 158
  • TABLE 117 SWITZERLAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 158
  • TABLE 118 SWITZERLAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 158
  • TABLE 119 SWITZERLAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 159
  • TABLE 120 RUSSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 160
  • TABLE 121 RUSSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 160
  • TABLE 122 RUSSIA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 160
  • TABLE 123 RUSSIA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 161
  • TABLE 124 RUSSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 161
  • TABLE 125 RUSSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 161
  • TABLE 126 RUSSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 162
  • TABLE 127 BELGIUM SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 163
  • TABLE 128 BELGIUM SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 163
  • TABLE 129 BELGIUM VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 163
  • TABLE 130 BELGIUM BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 164
  • TABLE 131 BELGIUM SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 164
  • TABLE 132 BELGIUM SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 164
  • TABLE 133 BELGIUM SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 165
  • TABLE 134 TURKEY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 166
  • TABLE 135 TURKEY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 166
  • TABLE 136 TURKEY VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 166
  • TABLE 137 TURKEY BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 167
  • TABLE 138 TURKEY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 167
  • TABLE 139 TURKEY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 167
  • TABLE 140 TURKEY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 168
  • TABLE 141 REST OF EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 169
  • TABLE 142 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 174
  • TABLE 143 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 174
  • TABLE 144 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 174
  • TABLE 145 ASIA-PACIFIC VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 175
  • TABLE 146 ASIA-PACIFIC BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 175
  • TABLE 147 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 175
  • TABLE 148 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 176
  • TABLE 149 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 176
  • TABLE 150 CHINA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 177
  • TABLE 151 CHINA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 177
  • TABLE 152 CHINA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 177
  • TABLE 153 CHINA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 178
  • TABLE 154 CHINA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 178
  • TABLE 155 CHINA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 178
  • TABLE 156 CHINA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 179
  • TABLE 157 JAPAN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 180
  • TABLE 158 JAPAN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 180
  • TABLE 159 JAPAN VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 180
  • TABLE 160 JAPAN BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 181
  • TABLE 161 JAPAN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 181
  • TABLE 162 JAPAN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 181
  • TABLE 163 JAPAN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 182
  • TABLE 164 INDIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 183
  • TABLE 165 INDIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 183
  • TABLE 166 INDIA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 183
  • TABLE 167 INDIA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 184
  • TABLE 168 INDIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 184
  • TABLE 169 INDIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 184
  • TABLE 170 INDIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 185
  • TABLE 171 SOUTH KOREA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 186
  • TABLE 172 SOUTH KOREA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 186
  • TABLE 173 SOUTH KOREA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 186
  • TABLE 174 SOUTH KOREA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 187
  • TABLE 175 SOUTH KOREA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 187
  • TABLE 176 SOUTH KOREA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 187
  • TABLE 177 SOUTH KOREA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 188
  • TABLE 178 AUSTRALIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 189
  • TABLE 179 AUSTRALIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 189
  • TABLE 180 AUSTRALIA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 189
  • TABLE 181 AUSTRALIA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 190
  • TABLE 182 AUSTRALIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 190
  • TABLE 183 AUSTRALIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 190
  • TABLE 184 AUSTRALIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 191
  • TABLE 185 SINGAPORE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 192
  • TABLE 186 SINGAPORE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 192
  • TABLE 187 SINGAPORE VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 192
  • TABLE 188 SINGAPORE BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 193
  • TABLE 189 SINGAPORE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 193
  • TABLE 190 SINGAPORE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 193
  • TABLE 191 SINGAPORE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 194
  • TABLE 192 THAILAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 195
  • TABLE 193 THAILAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 195
  • TABLE 194 THAILAND VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 195
  • TABLE 195 THAILAND BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 196
  • TABLE 196 THAILAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 196
  • TABLE 197 THAILAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 196
  • TABLE 198 THAILAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 197
  • TABLE 199 MALAYSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 198
  • TABLE 200 MALAYSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 198
  • TABLE 201 MALAYSIA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 198
  • TABLE 202 MALAYSIA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 199
  • TABLE 203 MALAYSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 199
  • TABLE 204 MALAYSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 199
  • TABLE 205 MALAYSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 200
  • TABLE 206 INDONESIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 201
  • TABLE 207 INDONESIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 201
  • TABLE 208 INDONESIA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 201
  • TABLE 209 INDONESIA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 202
  • TABLE 210 INDONESIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 202
  • TABLE 211 INDONESIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 202
  • TABLE 212 INDONESIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 203
  • TABLE 213 PHILIPPINES SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 204
  • TABLE 214 PHILIPPINES SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 204
  • TABLE 215 PHILIPPINES VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 204
  • TABLE 216 PHILIPPINES BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 205
  • TABLE 217 PHILIPPINES SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 205
  • TABLE 218 PHILIPPINES SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 205
  • TABLE 219 PHILIPPINES SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 206
  • TABLE 220 REST OF ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 207
  • TABLE 221 SOUTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 212
  • TABLE 222 SOUTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 212
  • TABLE 223 SOUTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 212
  • TABLE 224 SOUTH AMERICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 213
  • TABLE 225 SOUTH AMERICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 213
  • TABLE 226 SOUTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 213
  • TABLE 227 SOUTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 214
  • TABLE 228 SOUTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 214
  • TABLE 229 BRAZIL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 215
  • TABLE 230 BRAZIL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 215
  • TABLE 231 BRAZIL VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 215
  • TABLE 232 BRAZIL BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 216
  • TABLE 233 BRAZIL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 216
  • TABLE 234 BRAZIL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 216
  • TABLE 235 BRAZIL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 217
  • TABLE 236 ARGENTINA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 218
  • TABLE 237 ARGENTINA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 218
  • TABLE 238 ARGENTINA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 218
  • TABLE 239 ARGENTINA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 219
  • TABLE 240 ARGENTINA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 219
  • TABLE 241 ARGENTINA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 219
  • TABLE 242 ARGENTINA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 220
  • TABLE 243 REST OF SOUTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 221
  • TABLE 244 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 226
  • TABLE 245 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 226
  • TABLE 246 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 226
  • TABLE 247 MIDDLE EAST AND AFRICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 227
  • TABLE 248 MIDDLE EAST AND AFRICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 227
  • TABLE 249 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 227
  • TABLE 250 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 228
  • TABLE 251 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 228
  • TABLE 252 SOUTH AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 229
  • TABLE 253 SOUTH AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 229
  • TABLE 254 SOUTH AFRICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 229
  • TABLE 255 SOUTH AFRICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 230
  • TABLE 256 SOUTH AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 230
  • TABLE 257 SOUTH AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 230
  • TABLE 258 SOUTH AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 231
  • TABLE 259 SAUDI ARABIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 232
  • TABLE 260 SAUDI ARABIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 232
  • TABLE 261 SAUDI ARABIA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 232
  • TABLE 262 SAUDI ARABIA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 233
  • TABLE 263 SAUDI ARABIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 233
  • TABLE 264 SAUDI ARABIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 233
  • TABLE 265 SAUDI ARABIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 234
  • TABLE 266 U.A.E SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 235
  • TABLE 267 U.A.E SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 235
  • TABLE 268 U.A.E VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 235
  • TABLE 269 U.A.E BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 236
  • TABLE 270 U.A.E SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 236
  • TABLE 271 U.A.E SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 236
  • TABLE 272 U.A.E SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 237
  • TABLE 273 ISRAEL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 238
  • TABLE 274 ISRAEL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 238
  • TABLE 275 ISRAEL VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 238
  • TABLE 276 ISRAEL BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 239
  • TABLE 277 ISRAEL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 239
  • TABLE 278 ISRAEL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 239
  • TABLE 279 ISRAEL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 240
  • TABLE 280 EGYPT SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 241
  • TABLE 281 EGYPT SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 241
  • TABLE 282 EGYPT VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 241
  • TABLE 283 EGYPT BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 242
  • TABLE 284 EGYPT SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 242
  • TABLE 285 EGYPT SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 242
  • TABLE 286 EGYPT SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 243
  • TABLE 287 REST OF MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 244

LIST OF FIGURES

  • FIGURE 1 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION 33
  • FIGURE 2 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DATA TRIANGULATION 36
  • FIGURE 3 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DROC ANALYSIS 37
  • FIGURE 4 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 38
  • FIGURE 5 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 38
  • FIGURE 6 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS 40
  • FIGURE 7 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID 41
  • FIGURE 8 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: END USER COVERAGE GRID 42
  • FIGURE 9 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS 43
  • FIGURE 10 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION 46
  • FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF INFECTIOUS DISEASES IS EXPECTED TO DRIVE THE GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN THE FORECAST PERIOD 47
  • FIGURE 12 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN 2022 & 2029 47
  • FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD 48
  • FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET MANUFACTURERS IN THE FORECAST PERIOD 49
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET 57
  • FIGURE 16 TOTAL CASES OF COVID-19 IN NORTH AMERICA 58
  • FIGURE 17 TOTAL CASES OF COVID-19 IN EUROPE 59
  • FIGURE 18 NATIONAL HEALTH EXPENDITURE VS MEDICAL DEVICE EXPENDITURE, U.S., 2019 63
  • FIGURE 19 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, 2021 67
  • FIGURE 20 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, 2022-2029 (USD MILLION) 68
  • FIGURE 21 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, CAGR (2022-2029) 68
  • FIGURE 22 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, LIFELINE CURVE 69
  • FIGURE 23 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2021 74
  • FIGURE 24 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2022-2029 (USD MILLION) 75
  • FIGURE 25 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, CAGR (2022-2029) 75
  • FIGURE 26 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, LIFELINE CURVE 76
  • FIGURE 27 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2021 84
  • FIGURE 28 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2022-2029 (USD MILLION) 85
  • FIGURE 29 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, CAGR (2022-2029) 85
  • FIGURE 30 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, LIFELINE CURVE 86
  • FIGURE 31 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2021 94
  • FIGURE 32 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2022-2029 (USD MILLION) 95
  • FIGURE 33 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, CAGR (2022-2029) 95
  • FIGURE 34 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, LIFELINE CURVE 96
  • FIGURE 35 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2021 103
  • FIGURE 36 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2022-2029 (USD MILLION) 104
  • FIGURE 37 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, CAGR (2022-2029) 104
  • FIGURE 38 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE 105
  • FIGURE 39 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2021) 112
  • FIGURE 40 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY REGION (2021 ) 113
  • FIGURE 41 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY REGION (2022 & 2029) 113
  • FIGURE 42 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY REGION (2021 & 2029) 114
  • FIGURE 43 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT AND SERVICES (2022-2029) 114
  • FIGURE 44 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2021) 117
  • FIGURE 45 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021) 118
  • FIGURE 46 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2029) 118
  • FIGURE 47 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2029) 119
  • FIGURE 48 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT AND SERVICES (2022-2029) 119
  • FIGURE 49 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2021) 133
  • FIGURE 50 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021) 134
  • FIGURE 51 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2029) 134
  • FIGURE 52 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2029) 135
  • FIGURE 53 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT AND SERVICES (2022-2029) 135
  • FIGURE 54 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2021) 171
  • FIGURE 55 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021) 172
  • FIGURE 56 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2029) 172
  • FIGURE 57 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2029) 173
  • FIGURE 58 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT AND SERVICES (2022-2029) 173
  • FIGURE 59 SOUTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2021) 209
  • FIGURE 60 SOUTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2029) 210
  • FIGURE 61 SOUTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2029) 210
  • FIGURE 62 SOUTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2029) 211
  • FIGURE 63 SOUTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT AND SERVICES (2022-2029) 211
  • FIGURE 64 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2021) 223
  • FIGURE 65 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021) 224
  • FIGURE 66 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2029) 224
  • FIGURE 67 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2029) 225
  • FIGURE 68 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT AND SERVICES (2022-2029) 225
  • FIGURE 69 GLOBAL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY SHARE 2021 (%) 245
  • FIGURE 70 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY SHARE 2021 (%) 246
  • FIGURE 71 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY SHARE 2021 (%) 247
  • FIGURE 72 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY SHARE 2021 (%) 248